Dataset Information

A Metal-Dependant Formate Dehydrogenase Advances the Formate Bio-economy

ABSTRACT: In this manuscript a multi-subunit metal dependent FDH is functionally expressed in a strain of E. coli engineered to assimilate all energy and biomass from formate. The replacement of the previously described FDH with this new, faster FDH allows for improved growth parameters rivaling natural formatotrophs for the first time. This new, robsulty growing formatotrophic E. coli was engineered to produce mevalonate and achieved the highest reported titer for any bioproduct from formate in fed batch mode. Finally the authors explored bioproducion from electrochemically-derived and lignin-derived formate, demonstrating the first example of a bioproduct produced using liginin-derived formate as a feedstock.

INSTRUMENT(S):

ORGANISM(S): Escherichia Coli

SUBMITTER: Christopher Petzold

LAB HEAD: Christopher J.

PROVIDER: PXD059132 | Pride | 2025-07-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 77

Publications

Fast growth and high-titer bioproduction from renewable formate via metal-dependent formate dehydrogenase in Escherichia coli.

Cowan Aidan E AE Hillers Mason M Rainaldi Vittorio V Collas Florent F Choudhary Hemant H Zakaria Basem S BS Bieberach Gregory G GG Carruthers David N DN Grabovac Maxwell M Gin Jennifer W JW Cawthon Bridgie B Chen Yan Y Turumtay Emine Akyuz EA Baidoo Edward E K EEK Petzold Christopher J CJ Feist Adam M AM Tejedor-Sanz Sara S Kensy Frank F Simmons Blake A BA Keasling Jay D JD Claassens Nico J NJ

Nature communications 20250701 1

Microbial bioproduction using one-carbon (C1) feedstocks has the potential to decarbonize the manufacturing of materials, fuels, and chemicals. Formate is a promising C1 feedstock, and the realization of industrial, formatotrophic platform organisms is a key goal for C1-based bioproduction. So far, a major limitation for synthetic formatotrophy has been slow energy supply due to slow formate dehydrogenase activity. Here, we implement a fast, metal-dependent formate dehydrogenase complex in a syn ...[more]

PMID: 40593698

Similar Datasets

Project description:Steroidal alkaloids are FDA-approved drugs (e.g., Zytiga) and promising drug candidates/leads (e.g., cyclopamine); yet many of the ≥ 697 known steroidal alkaloid natural products remain underutilized as drugs because it can be challenging to scale their biosynthesis in their producing organisms. Cyclopamine is a steroidal alkaloid produced by corn lily (Veratrum spp.) plants, and it is an inhibitor of the Hedgehog (Hh) signaling pathway. Therefore, cyclopamine is an important drug candidate/lead to treat human diseases that are associated with dysregulated Hh signaling, such as basal cell carcinoma and acute myeloid leukemia. Cyclopamine and its semi-synthetic derivatives have been studied in (pre)clinical trials as Hh inhibitor-based drugs. However, challenges in scaling the production of cyclopamine have slowed efforts to improve its 1 efficacy and safety profile through (bio)synthetic derivatization, often limiting drug development to synthetic analogs of cyclopamine such as the FDA-approved drugs Odomzo, Daurismo, and Erivedge. If a platform for the scalable and sustainable production of cyclopamine were established, then its (bio)synthetic derivatization, clinical development, and, ultimately, widespread distribution could be accelerated. Ongoing efforts to achieve this goal include the biosynthesis of cyclopamine in Veratrum plant cell culture and the semi-/total chemical synthesis of cyclopamine. Herein, this work advances efforts towards a promising future approach: the biosynthesis of cyclopamine in engineered microorganisms. We completed the heterologous microbial production of verazine (biosynthetic precursor to cyclopamine) from simple sugars (i.e., glucose and galactose) in engineered Saccharomyces cerevisiae (S. cerevisiae) through the inducible upregulation of the native yeast mevalonate and lanosterol biosynthetic pathways, diversion of biosynthetic flux from ergosterol (i.e., native sterol in S. cerevisiae) to cholesterol (i.e., biosynthetic precursor to verazine), and expression of a refactored five-step verazine biosynthetic pathway containing eight heterologous enzymes sourced from seven different species. Importantly, S. cerevisiae-produced verazine was indistinguishable via liquid chromatography-mass spectrometry from both a commercial standard (Veratrum spp. plant-produced) and Nicotiana benthamiana-produced verazine. To the best of our knowledge, this is the first report describing the heterologous production of a steroidal alkaloid in an engineered yeast. Verazine production was increased through design-build-test-learn cycles to a final titer of 27 ± 2 μg/L (1.7 ± 0.1 μg/g DCW). Together, this research lays the groundwork for future microbial biosynthesis of cyclopamine, (bio)synthetic derivatives of cyclopamine, and other steroidal alkaloid natural products.

			Action	DRS
	8_17_2-R1.raw	Raw
	8_17_2-R2.raw	Raw
	8_17_2-R3.raw	Raw
	8_17_4-R1.raw	Raw
	8_17_4-R2.raw	Raw